“Schistosomiasis ranks among the most devastating poverty related neglected diseases - and a schistosomiasis vaccine would be a game changer both for global public health and poverty reduction,” said Dr. Peter Hotez, dean of the National School of Tropical Medicine at Baylor College of Medicine. A team of researchers at the George Washington University have received funding from the National Institutes of Health for a Phase Ib clinical trial for a Schistosomiasis vaccine in an endemic area of Brazil. Take a look at this article to read more about the Schistosoma Vaccine.
Schistosoma Vaccine to Enter Phase Ib Clinical Trial
Latest News
This was a phase 1, double-blind trial to examine the safety and immunogenicity of a replication-competent recombinant vesicular stomatitis virus-vectored vaccine to reduce the risk of infection and severe illness from Lassa Fever.
The GW VRU is pleased to share the findings from a Phase 2 clinical trial that evaluated the effects of omicron-based COVID-19 vaccines in providing an increased level of protection against COVID-19 infection. This study adds to the evidence that matching COVID-19 vaccines to the circulating…
A protective HIV vaccine will need to induce broadly neutralizing antibodies (bnAbs) in humans, but priming rare bnAb precursor B cells has been challenging. This study provides proof-of-concept for Env trimer-based GT approaches to activate bnAb precursors and induce affinity maturation on the…